Metrion have teamed up with Axxam, Nanion, SB Discovery and Sophion to deliver a series of presentations from drug discovery companies, companies that provide ion channel services to drug discovery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers.
Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery.
The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting and review the advances ion channel drug discovery.
08:00 | Registration and coffee | |
08:30 | Opening remarks | Dr Chris Mathes, Metrion Biosciences |
Session 1: Chaired by Daniel Sauter, Sophion Biosciences | ||
08:45 | Keynote | To be announced |
09:30 | Diminazene Reveals Unexpected ASIC Biology | John Gilchrist, Latigo Biotherapeutics |
10:00 | Subtype-Selective Modulation and Rescue of HCN1 Channel Mutants | Jun Chen, Genentech |
10:30 | Coffee | |
Session 2: Chaired by Jean Francois Rolland, Axxam | ||
11:00 | Targeting Ion Channels with De Novo Designed Mini Proteins | Stefan Pless, University of Copenhagen |
11:30 | Mining the Voltage-Gated Na+ Channel for Neurotherapeutics Development | Fernanda Laezza, University of Texas |
12:00 | To be announced | Jeremiah Osteen, Vertex Pharmaceuticals |
12:30 | Lunch | |
Session 3: Chaired by Niels Fertig, Nanion | ||
13:30 | Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain | Jose Matta, Rapport Therapeutics |
14:00 | Targeting AMPA Receptors in Complex with TARP-g8 for Epilepsy and Pain | Xi Huang, Toronto Hospital for Sick Children |
14:30 | To be announced | Victoria Assimon, Maze Therapeutics |
15:00 | Coffee | |
Session 4: Chaired by Steve Jenkinson, Metrion Biosciences | ||
15:30 | To be announced | Kris Kahlig, Praxis Precision Medicines |
16:00 | Reverse Use-Dependence of Nav1.8 Inhibitors GABA B Receptor Modulation of Membrane Excitability in Human Pluripotent Stem Cell-Derived Sensory Neurons by Baclofen and α-conotoxin Vc1.1 | David Adams, University of Wollongong |
16:30 | To be announced | Nina Ottossen, Linkoping University |
17:00 | Closing remarks | Niels Fertig, Nanion |
17:15 | Close |